Skip to main content
Clinical Trials/NL-OMON44254
NL-OMON44254
Recruiting
Not Applicable

on-invasive assessment of lung remodeling in patients with idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) using [11C]-Nintedanib or [18F]-FLT PET imaging. - Imaging the primary disease process in IPF and PAH

Vrije Universiteit0 sites90 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Vrije Universiteit
Enrollment
90
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • 1\. Diagnosis of IPF, according to ATS/ERS guidelines (ref Raghu AJRCCM 2011\)
  • Diagnosis of PAH, according to ESC/ERS guidelines (ref: Galie ERJ 2015\)
  • Unaffected BMPR2 mutation carrier
  • Normal control subjects
  • 2\. Age \>18 and \<80 years

Exclusion Criteria

  • \- Claustrophobia
  • \- Inability to provide informed consent
  • \- In case of IPF patients: pulmonary hypertension suspected by echocardiography or proven by right heart
  • catheterization
  • \- In case of PAH patients: TLC \< 70%pred or radiographic evidence of interstitial lung disease
  • \- In case of BMPR2 mutation carriers and normal control subjects, one or more of the following: abnormal
  • spirometry, TLC \< 70%, echocardiographic evidence of pulmonary hypertension

Outcomes

Primary Outcomes

Not specified

Similar Trials